Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772686 | 1.00 | DPP3 (0.65) | DPP3OPRM1SLC6A2 | |
| SCHEMBL30610091 | 0.96 | DPP3 (0.69) | DPP3OPRM1 | |
| SCHEMBL29648960 | 0.96 | DPP3 (0.69) | DPP3OPRM1 | |
| SCHEMBL30659496 | 0.95 | DPP3 (0.64) | DPP3OPRM1 | |
| Endomorphin-1 SCHEMBL21811384 | 0.95 | — | — | |
| Endomorphin-1 SCHEMBL29577928 | 0.95 | — | — | |
| Endomorphin-1 SCHEMBL29379764 | 0.95 | — | — | |
| SCHEMBL20749886 | 0.95 | OPRM1 (0.63) | DPP3OPRM1SLC6A2 | |
| Endomorphin-1 SCHEMBL29390342 | 0.95 | — | — | |
| SCHEMBL14242750 | 0.95 | OPRM1 (0.63) | DPP3OPRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20230415070-A1 | EUTECTIC COMPOSITIONS, METHODS AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2023-12-28 | — | — | US | disclosed |
| EP-3716948-B1 | NOVEL ANALGESIC PHARMACEUTICAL FORMULATIONS AND USES THEREOF | CYTOGEL PHARMA LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4243952-A1 | EUTECTIC COMPOSITIONS, METHODS AND USES THEREOF | Universidade do Minho (PT) | 2023-09-20 | — | — | EP | disclosed |
| CN-116583338-A | Eutectic composition, method and use thereof | 米尼翁大学 | 2023-08-11 | — | — | CN | disclosed |
| US-20230212221-A1 | Novel Therapeutic Uses of Mu-Opiate Receptor Peptides | CYTOGEL PHARMA, LLC | 2023-07-06 | — | — | US | disclosed |
| US-11603385-B2 | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof | CYTOGEL PHARMA, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20220324908-A1 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | CYTOGEL PHARMA, LLC | 2022-10-13 | — | — | US | disclosed |
| US-20220249593-A1 | Materials and Methods for Treatment of Inflammation | CYTOGEL PHARMA, LLC | 2022-08-11 | — | — | US | disclosed |
| WO-2022101490-A1 | EUTECTIC COMPOSITIONS, METHODS AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2022-05-19 | — | — | WO | disclosed |
| US-11324798-B2 | Materials and methods for treatment of inflammation | CYTOGEL PHARMA, LLC (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | DPP3 123/4885OPRM1 2580/4885SLC6A2 2560/4885 |
| US-11324798-B2 | Materials and methods for treatment of inflammation | CALCA, CALCRL, CALCB | DPP3 384/4885OPRM1 115/4885SLC6A2 1617/4885 |
| US-20230212221-A1 | Novel Therapeutic Uses of Mu-Opiate Receptor Peptides | OPRL1, OPRM1, OPRK1 | DPP3 703/4885OPRM1 2/4885SLC6A2 405/4885 |
| US-20220324908-A1 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | OPRM1, OPRL1, OPRK1 | DPP3 1120/4885OPRM1 1/4885SLC6A2 452/4885 |
| US-20220249593-A1 | Materials and Methods for Treatment of Inflammation | CALCA, CALCRL, CALCB | DPP3 384/4885OPRM1 115/4885SLC6A2 1617/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | DPP3 1221/4885OPRM1 2774/4885SLC6A2 585/4885 |
| US-20230415070-A1 | EUTECTIC COMPOSITIONS, METHODS AND USES THEREOF | DGAT2, DLAT, DGKB | DPP3 3685/4885OPRM1 3974/4885SLC6A2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.